Reform Vs. Improvements: No Decision Yet On Fate Of EU Advanced Therapies Law
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory framework for gene therapy and tissue-engineered products is seen as inflexible and unclear, but policymakers have yet to decide on whether to fix what's there or aim for a legislative change.
You may also be interested in...
EMA's Action Plan To Support ATMPs Expected In Jan 2017
The European Medicines Agency's action plan to support the development of advanced therapy medicinal products will prioritize on actions that are feasible, will result in major gains without the need for a lot of effort and will not require legislative changes.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.